GlassScriptPhysician profile
Susan G Traxler
NPI 1700922747
$3,209.89
in general payments reported to CMS, 2019-2025
25 companies · $534 in 2025
The $534 reported for 2025 was more than what 94% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $415 · 2020: $183 · 2021: $356 · 2022: $609 · 2023: $538 · 2024: $576 · 2025: $534.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,648.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,647.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tris Pharma INC | $538.97 | 2019-2025 | Dyanavel Xr, Quillichew Er, Quillivant |
| Ironshore Pharmaceuticals INC. | $503.70 | 2019-2024 | Jornay Pm |
| Corium, LLC | $460.72 | 2021-2025 | Azstarys |
| Supernus Pharmaceuticals, INC. | $241.54 | 2021-2025 | Qelbree, Qelbree |
| Takeda Pharmaceuticals U.S.A., INC. | $178.42 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $160.91 | 2024-2025 | |
| Sobi, INC | $139.38 | 2019-2023 | |
| Cranial Technologies, INC | $137.08 | 2019-2025 | Doc Band |
| Neos Therapeutics, LP | $114.53 | 2019-2022 | |
| Glaxosmithkline, LLC. | $103.87 | 2019-2025 | Penmenvy, Bexsero |
| Sanofi Pasteur INC. | $95.94 | 2019-2025 | |
| Pfizer INC. | $67.99 | 2022-2023 | |
| Alk-Abello, INC | $67.87 | 2025 | Neffy, Grastek, Odactra |
| Adlon Therapeutics L.P. | $58.69 | 2020-2021 | |
| Merck Sharp & Dohme LLC | $55.31 | 2019-2024 | Gardasil 9, Vaxelis, Vaxneuvance |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kaleo, INC. | $44.82 | 2021 | |
| Noven Therapeutics, LLC | $38.67 | 2023 | Xelstrym |
| Arbor Pharmaceuticals, INC. | $34.46 | 2019 | |
| Collegium Pharmaceutical, INC. | $31.13 | 2025 | Jornay Pm |
| Vertical Pharmaceuticals, LLC | $27.84 | 2024 | Relexxii |
| Astrazeneca Pharmaceuticals LP | $27.81 | 2023 | Flumist Quadrivalent |
| Genentech USA, INC. | $21.53 | 2019 | |
| Biomerieux INC | $21.00 | 2025 | |
| Ultragenyx Pharmaceutical INC. | $20.42 | 2022 | |
| Allegis Pharmaceuticals, LLC | $17.29 | 2023 | Spinosad |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Susan Traxler listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.